Tribal Opioid Response
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Tribal Opioid Response program aims to combat the opioid overdose crisis in Tribal communities by enhancing access to FDA-approved medications for opioid use disorder and strengthening the full range of services related to prevention, treatment, and recovery support for opioid use disorder as well as co-occurring substance use disorders. In addition to opioid-related services, the program also addresses stimulant misuse and use disorders, including those involving cocaine and methamphetamine. This multifaceted approach supports communities in mitigating substance use challenges and improving health outcomes. The program is overseen by the Department of Health and Human Services through its Substance Abuse and Mental Health Services Administration (SAMHSA). Although specific solicitation details and locations are not provided, contact information for further inquiries is available through William Longinetti. This forecast opportunity was posted in March 2026, indicating future funding or program activities to support Tribal communities in addressing substance use disorders.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The purpose of the TOR program is to assist in addressing the opioid overdose crisis in Tribal communities by increasing access to FDA-approved medications for opioid use disorder, and supporting the continuum of prevention, treatment, and recovery support services for opioid use disorder and co-occurring substance use disorders. This program also supports prevention, treatment, and recovery support services for stimulant misuse and use disorders, including those involving cocaine and methamphetamine.
